Biocon Biologics Announces US FDA Approval for Jobevne^™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

Biocon Biologics announced that the US FDA has approved Jobevne^™, a biosimilar Bevacizumab for intravenous use. JOBEVNE is a VEGF inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis.